

1. REVLIMID [package insert]. Summit, NJ: Celgene Corp; 2019.
2. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2019.
3. Data on file. Celgene Corp; 2018.
4. Anderson KC. Therapeutic advances in relapsed or refractory multiple myeloma. *J Natl Compr Canc Netw*. 2013;11(5 suppl):676-679.
5. Hajek R. Strategies for the treatment of multiple myeloma in 2013: moving toward the cure. In: Hajek R, ed. *Multiple Myeloma*. IntechOpen; 2013. doi:10.5772/55366.
6. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. *J Hematol Oncol*. 2009;2:36.
7. POMALYST [package insert]. Summit, NJ: Celgene Corp; 2018.
8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Multiple Myeloma V.3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed June 25, 2019. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
9. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014;371(10):906-917.
10. Facon T, Kumar S, Plesner T, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). Presented at: 60th ASH Annual Meeting and Exposition; December 4, 2018; San Diego, CA.
11. Targeted Therapy Side Effects: Skin Problems. American Cancer Society Website. <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/side-effects.html>. Revised December 27, 2019. Accessed February 4, 2020.
12. US Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0.
13. Managing Cancer-related Fatigue. American Cancer Society website. <https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/fatigue/managing-cancer-related-fatigue.html>. Revised October 22, 2018. Accessed January 30, 2020.

14. Diarrhea. American Cancer Society website.  
<https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/stool-or-urine-changes/diarrhea.html>. Revised July 29, 2019. Accessed January 30, 2020.
15. Miceli T, Colson K, Gavino M, Lilleby K; IMF Nurse Leadership Board. Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. *J Clin Oncol Nurs*. 2008;12(suppl 3):13-20.
16. Poon ML, Chng WJ. Is complete remission an important therapeutic aim in multiple myeloma? *Cancer Ther*. 2008;6:275-284.
17. Moreau P, Giralt SA. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. *Leuk Res*. 2012;36:S13-S18.
18. Roschewski M, Korde N, Wu SP, Landgren O. Pursuing the curative blueprint for early myeloma. *Blood*. 2013;122(4):486-490.
19. Borrello I. Can we change the disease biology of multiple myeloma? *Leuk Res*. 2012;36(suppl 1):S3-S12.
20. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. *Nat Rev Cancer*. 2012;12(5):335-348.
21. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. *Blood*. 2015;125(20):3076-3084.